This is an interesting topic, and this combined modality within the context of serum BDNF levels and the analysis of CSF, markers of neuroimaging (e.g., hippocampal atrophy), and genetic profiling may increase detection of disease in early stages and monitoring of therapeutic efficacy. This evidence concerns the gene BDNF and hippocampal atrophy.